Kiniksa Pharmaceuticals International, PLC (KNSA) intrinsic value & 10-year financials
Kiniksa Pharmaceuticals International, PLC (KNSA) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 104.8% a year to $677.6M, with an average return on invested capital of -32.4%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $78.59
- Market cap
- $6.2B
- Revenue (FY2025)
- $677.6M
- Revenue growth (10-yr CAGR)
- 104.8%
- ROIC (10-yr avg)
- -32.4%
- Free cash flow (FY2025)
- $136.4M
KNSA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $677.6M | $59.0M | $0.75 | $136.4M | 11.4% | 15.3% |
| FY2024 | $423.2M | -$43.2M | -$0.60 | $25.4M | -10.8% | -15.1% |
| FY2023 | $270.3M | $14.1M | $0.20 | $13.2M | -9.3% | -4.1% |
| FY2022 | $220.2M | $183.4M | $2.60 | $5.7M | 4.4% | 5.7% |
| FY2021 | $38.5M | -$157.9M | -$2.30 | -$126.7M | -406.4% | -116.9% |
| FY2020 | — | -$161.4M | -$2.61 | -$136.8M | — | -82.3% |
| FY2019 | — | -$161.9M | -$2.99 | -$161.6M | — | -93.5% |
| FY2018 | — | -$103.2M | — | -$86.3M | — | -113.9% |
| FY2017 | — | -$64.9M | — | -$50.3M | — | 113.3% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Kiniksa Pharmaceuticals International, plc revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Kiniksa Pharmaceuticals International, plc has historically struggled to out-earn its cost of capital, averaging just -41.6% ROIC.
Kiniksa Pharmaceuticals International, plc capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Kiniksa Pharmaceuticals International, plc is modeled at -33.9% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-38.41 per share.